ClinicalTrials.gg
CompletedNCT00687973EXPLORUpdated Mar 11, 2011Results posted

Effect of the Fixed Dose Combination Amlodipine/Valsartan on Central Aortic Blood Pressure in Uncontrolled Essential Hypertension With Amlodipine 5 mg

A Phase 4 interventional study of Valsartan/amlodipine 80/5 mg tablets and Amlodipine 5 mg capsules in Hypertension, sponsored by Novartis Pharmaceuticals. Completed at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-03-11.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
393
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 227 studies in Hypertension by Novartis — 4 open to participants now, 5 under way, none of them phase 3. Hypertension · Novartis.

Enrollment
96th of 222
393 · median 309
Started
2008
with 24 others
Phase 4
67 of 227
none open now
Registered
132nd of 227
by date

Among the 227 studies in Hypertension by Novartis, this one is the 96th largest by enrollment of the 222 interventional ones that give a count, is one of 25 that started in 2008, is one of 67 in phase 4, and was the 132nd registered.

Hypertension

6,120 studies on the registry are indexed under Hypertension; 909 are open to participants now.

Browse Hypertension studies →

Open to participants now

4 of the 227 studies in Hypertension by Novartis are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 558 Hypertension studies recruiting now, 265 (47%) set no upper age limit and 197 (35%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 227 studies in Hypertension by Novartis, or all of them as a file.
02

Study summary

Assess that for an equivalent brachial blood pressure (BP)lowering, a fixed dose combination amlodipine/valsartan based regimen reduces central aortic BP pressure to a larger extent than an atenolol/amlodipine combination based regimen.

03

Conditions studied

  • Hypertension

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female patients 18 years of age or older
  • Hypertension defined by MSDBP > 90 and or MSSBP > 140 mmHg, MSDBP > 80 mmHg, or/and MSSBP > 130 mmHg if diabetes or chronic renal impairment uncontrolled under their previous therapy, or untreated , or experiencing unacceptable side effects
  • Written to participate in the study prior to any study procedures

Exclusion criteria

Exclusion Criteria:

  • Severe hypertension (grade 3 WHO classification MSDBP > 110 mmHg and/or MSSBP > 180 mmHg)
  • Evidence of a secondary form of hypertension
  • Type 1 diabetes mellitus
  • History of congestive heart failure, unstable coronary insufficiency, life threatening arrhythmia, significant valvular disease, second or third degree heart block etc.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
393 participants (actual)

Study arms

  • Experimental
    Valsartan/amlodipine 160/10 mg

    Patients were treated with valsartan/amlodipine 80/5 mg for 8 weeks followed by forced uptitration to valsartan/amlodipine 160/10 mg for 16 weeks. All doses were taken orally once daily in the morning, except on days when clinic visits were scheduled.

    Drug: Valsartan/amlodipine 80/5 mg tablets

  • Active comparator
    Atenolol/amlodipine 100/10 mg

    Patients were treated with atenolol/amlodipine 50/5 mg for 8 weeks followed by forced uptitration to atenolol/amlodipine 100/10 mg for 16 weeks. All doses were taken orally once daily in the morning, except on days when clinic visits were scheduled.

    Drug: Amlodipine 5 mg capsules · Drug: Amlodipine 10 mg capsules · Drug: Atenolol 50 mg tablets · Drug: Atenolol 100 mg tablets

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Baseline of Central Systolic Blood Pressure (SBP) at Week 24 (Radial Measurement)

    Time frame: Baseline and Week 24

Secondary outcomes

  1. Change From Baseline of Central Systolic Blood Pressure (SBP) at Week 8 (Radial Measurement)

    Time frame: Baseline and Week 8

  2. Change From Baseline of Central Pulse Pressure at Week 24 (Radial Measurement)

    Time frame: Baseline and Week 24

  3. Change From Baseline of Augmentation Index (Aix) at Week 8

    To calculate the blood pressure augmentation index, the inflection point of the pressure curve corresponding to the return of the reflection wave was determined. The ratio between the pressure located above and below the inflection point was calculated.

    Time frame: Baseline and Week 8

  4. Change From Baseline of Aix at Week 24

    Time frame: Baseline and Week 24

  5. Change From Baseline of Aix Corrected to Heart Rate at Week 24

    The heart rate correction was computed by a multivariate model analysis

    Time frame: Baseline and Week 24

  6. Change From Baseline of Pulse Wave Velocity at Week 24 (Radial Measurement)

    Time frame: Baseline and Week 24

  7. Change From Baseline of Brachial SBP/DBP at Week 24 (Tonometry Center)

    Applanation tonometry is a measurement of aortic pressure and vascular stiffness. To assess the central aortic blood pressure, it is necessary to calibrate the applanation tonometry device using the brachial blood pressure.

    Time frame: Baseline and Week 24

  8. Change From Baseline of Brachial Pulse Pressure at Week 24 (Tonometry Center)

    Time frame: Baseline and Week 24

  9. Change From Baseline of SBP/DBP at Week 24 (Office BP)

    Time frame: Baseline and Week 24

  10. Change From Baseline of Pulse Pressure at Week 24 (Office BP)

    Time frame: Baseline and Week 24

07

Results

Posted Jan 21, 2011

Participant flow

Participant flow — Overall Study
MilestoneValsartan/Amlodipine 160/10 mgAtenolol/Amlodipine 100/10 mg
Started193200
Completed169162
Not completed2438
Withdrew: Adverse event1828
Withdrew: Lack of efficacy23
Withdrew: Protocol violation12
Withdrew: Administrative reasons02
Withdrew: Withdrawal by subject33

Outcome measures

PrimaryChange From Baseline of Central Systolic Blood Pressure (SBP) at Week 24 (Radial Measurement)
Time frame:
Baseline and Week 24
Reported as:
Least squares mean · mmHg
Change From Baseline of Central Systolic Blood Pressure (SBP) at Week 24 (Radial Measurement)
mmHgValsartan/Amlodipine 160/10 mgAtenolol/Amlodipine 100/10 mg
Change From Baseline of Central Systolic Blood Pressure (SBP) at Week 24 (Radial Measurement)-13.65 ± 1.15-9.7 ± 1.09
SecondaryChange From Baseline of Central Systolic Blood Pressure (SBP) at Week 8 (Radial Measurement)
Time frame:
Baseline and Week 8
Reported as:
Least squares mean · mmHg
Change From Baseline of Central Systolic Blood Pressure (SBP) at Week 8 (Radial Measurement)
mmHgValsartan/Amlodipine 160/10 mgAtenolol/Amlodipine 100/10 mg
Change From Baseline of Central Systolic Blood Pressure (SBP) at Week 8 (Radial Measurement)-10.92 ± 1.18-8.3 ± 1.12
SecondaryChange From Baseline of Central Pulse Pressure at Week 24 (Radial Measurement)
Time frame:
Baseline and Week 24
Reported as:
Least squares mean · mmHg
Change From Baseline of Central Pulse Pressure at Week 24 (Radial Measurement)
mmHgValsartan/Amlodipine 160/10 mgAtenolol/Amlodipine 100/10 mg
Change From Baseline of Central Pulse Pressure at Week 24 (Radial Measurement)-5.5 ± 0.65-1.7 ± 0.63
SecondaryChange From Baseline of Augmentation Index (Aix) at Week 8

To calculate the blood pressure augmentation index, the inflection point of the pressure curve corresponding to the return of the reflection wave was determined. The ratio between the pressure located above and below the inflection point was calculated.

Time frame:
Baseline and Week 8
Reported as:
Least squares mean · Ratio
Change From Baseline of Augmentation Index (Aix) at Week 8
RatioValsartan/Amlodipine 160/10 mgAtenolol/Amlodipine 100/10 mg
Change From Baseline of Augmentation Index (Aix) at Week 8-2.21 ± 0.783.61 ± 0.76
SecondaryChange From Baseline of Aix at Week 24
Time frame:
Baseline and Week 24
Reported as:
Least squares mean · Ratio
Change From Baseline of Aix at Week 24
RatioValsartan/Amlodipine 160/10 mgAtenolol/Amlodipine 100/10 mg
Change From Baseline of Aix at Week 24-4.10 ± 0.722.40 ± 0.70
SecondaryChange From Baseline of Aix Corrected to Heart Rate at Week 24

The heart rate correction was computed by a multivariate model analysis

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · Ratio
Change From Baseline of Aix Corrected to Heart Rate at Week 24
RatioValsartan/Amlodipine 160/10 mgAtenolol/Amlodipine 100/10 mg
Change From Baseline of Aix Corrected to Heart Rate at Week 24-4.12 ± 0.67-2.43 ± 0.66
SecondaryChange From Baseline of Pulse Wave Velocity at Week 24 (Radial Measurement)
Time frame:
Baseline and Week 24
Reported as:
Least squares mean · m/s
Change From Baseline of Pulse Wave Velocity at Week 24 (Radial Measurement)
m/sValsartan/Amlodipine 160/10 mgAtenolol/Amlodipine 100/10 mg
Change From Baseline of Pulse Wave Velocity at Week 24 (Radial Measurement)-0.98 ± 0.18-0.95 ± 0.17
SecondaryChange From Baseline of Brachial SBP/DBP at Week 24 (Tonometry Center)

Applanation tonometry is a measurement of aortic pressure and vascular stiffness. To assess the central aortic blood pressure, it is necessary to calibrate the applanation tonometry device using the brachial blood pressure.

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · mmHg
Change From Baseline of Brachial SBP/DBP at Week 24 (Tonometry Center)
mmHgValsartan/Amlodipine 160/10 mgAtenolol/Amlodipine 100/10 mg
SBP-12.93 ± 1.14-11.78 ± 1.11
DBP-7.85 ± 0.70-7.94 ± 0.68
SecondaryChange From Baseline of Brachial Pulse Pressure at Week 24 (Tonometry Center)
Time frame:
Baseline and Week 24
Reported as:
Least squares mean · mmHg
Change From Baseline of Brachial Pulse Pressure at Week 24 (Tonometry Center)
mmHgValsartan/Amlodipine 160/10 mgAtenolol/Amlodipine 100/10 mg
Change From Baseline of Brachial Pulse Pressure at Week 24 (Tonometry Center)-5.02 ± 0.72-3.66 ± 0.70
SecondaryChange From Baseline of SBP/DBP at Week 24 (Office BP)
Time frame:
Baseline and Week 24
Reported as:
Least squares mean · mmHg
Change From Baseline of SBP/DBP at Week 24 (Office BP)
mmHgValsartan/Amlodipine 160/10 mgAtenolol/Amlodipine 100/10 mg
SBP-14.49 ± 1.08-16.94 ± 1.07
DBP-8.17 ± 0.72-10.45 ± 0.71
SecondaryChange From Baseline of Pulse Pressure at Week 24 (Office BP)
Time frame:
Baseline and Week 24
Reported as:
Least squares mean · mmHg
Change From Baseline of Pulse Pressure at Week 24 (Office BP)
mmHgValsartan/Amlodipine 160/10 mgAtenolol/Amlodipine 100/10 mg
Change From Baseline of Pulse Pressure at Week 24 (Office BP)-6.32 ± 0.81-6.48 ± 0.81

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Amlodipine 5 mg—3/393 (0.8%)10/393 (2.5%)
Valsartan/Amlodipine 160/10 mg—4/193 (2.1%)30/193 (15.5%)
Atenolol/Amlodipine 100/10 mg—4/200 (2%)31/200 (15.5%)
Most frequent serious events
Showing 10 of 14
Most frequent serious events
EventAmlodipine 5 mgValsartan/Amlodipine 160/10 mgAtenolol/Amlodipine 100/10 mg
Colitis ulcerativeGastrointestinal disorders0/3931/1930/200
Lip and/or oral cavity cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/3931/1930/200
Pulmonary embolismRespiratory, thoracic and mediastinal disorders0/3931/1930/200
Cyst removalSurgical and medical procedures0/3931/1930/200
Joint arthroplastySurgical and medical procedures0/3931/1930/200
Head injuryInjury, poisoning and procedural complications0/3930/1931/200
Neoplasm malignantNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/3930/1931/200
PregnancyPregnancy, puerperium and perinatal conditions0/3930/1931/200
Suicide attemptPsychiatric disorders0/3930/1931/200
Inguinal hernia repairSurgical and medical procedures0/3930/1931/200
Most frequent other events
Most frequent other events
EventAmlodipine 5 mgValsartan/Amlodipine 160/10 mgAtenolol/Amlodipine 100/10 mg
Oedema peripheralGeneral disorders10/39330/19331/200

Baseline characteristics

Age Continuous
Age Continuous(years)Valsartan/Amlodipine 160/10 mgAtenolol/Amlodipine 100/10 mgTotal
Mean57.5 ± 9.9456.2 ± 11.0956.9 ± 10.55
Sex: Female, Male
Sex: Female, Male(Participants)Valsartan/Amlodipine 160/10 mgAtenolol/Amlodipine 100/10 mgTotal
Female82101183
Male11199210
Region of Enrollment
Region of Enrollment(participants)Valsartan/Amlodipine 160/10 mgAtenolol/Amlodipine 100/10 mgTotal
France193200393
08

Study locations

1 site
  • 2 & 4 rue Lionel Terray BP 308
    Rueil-Malmaison, 92506, France
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2008, a primary completion of Jan 2009 and a completion of Jan 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2011, 2 years after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 20, 2008
First posted
Jun 2, 2008
Start
Jan 2008
Primary completionActual
Jan 2009
CompletionActual
Jan 2009
Results first posted
Jan 21, 2011
Last update
Mar 11, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 11, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00687973
First posted
Jun 2, 2008
Start date
Jan 2008
Primary completion
Jan 2009
Completion
Jan 2009
Results posted
Jan 21, 2011
Last update
Mar 11, 2011

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion